BR9603429A - Derivado de 11-(fenila substituída) estra-4,9-dieno processo de preparação do mesmo composição farmacêutica e uso deste derivado - Google Patents

Derivado de 11-(fenila substituída) estra-4,9-dieno processo de preparação do mesmo composição farmacêutica e uso deste derivado

Info

Publication number: BR9603429A
Authority: BR; Brazil
Prior art keywords: derivative; estra; pharmaceutical composition; preparation process; substituted phenyl
Prior art date: 1995-08-17

Application number

BR9603429A

Other languages

English (en)

Inventor

Ronald Gebhard

Original Assignee

Akzo Nobel Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-08-17

Filing date

1996-08-14

Publication date

1998-05-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8220570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9603429(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-08-14 Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv

1998-05-12 Publication of BR9603429A publication Critical patent/BR9603429A/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/006—Ketals at position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0016—Oximes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/0026—Oxygen-containing hetero ring cyclic ketals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Ophthalmology & Optometry (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Addiction (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BR9603429A 1995-08-17 1996-08-14 Derivado de 11-(fenila substituída) estra-4,9-dieno processo de preparação do mesmo composição farmacêutica e uso deste derivado BR9603429A (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP95202229		1995-08-17

Publications (1)

Publication Number	Publication Date
BR9603429A true BR9603429A (pt)	1998-05-12

Family

ID=8220570

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9603429A BR9603429A (pt)	1995-08-17	1996-08-14	Derivado de 11-(fenila substituída) estra-4,9-dieno processo de preparação do mesmo composição farmacêutica e uso deste derivado

Country Status (25)

Country	Link
US (1)	US6011025A (pt)
EP (1)	EP0763541B1 (pt)
JP (1)	JP3977462B2 (pt)
KR (1)	KR100445376B1 (pt)
CN (1)	CN1129602C (pt)
AR (1)	AR003982A1 (pt)
AT (1)	ATE182596T1 (pt)
AU (1)	AU711369B2 (pt)
BR (1)	BR9603429A (pt)
CA (1)	CA2182771C (pt)
CZ (1)	CZ287740B6 (pt)
DE (1)	DE69603425T2 (pt)
DK (1)	DK0763541T3 (pt)
ES (1)	ES2137625T3 (pt)
GR (1)	GR3031116T3 (pt)
HU (1)	HU229023B1 (pt)
IL (1)	IL118974A (pt)
NO (1)	NO306257B1 (pt)
NZ (1)	NZ299181A (pt)
PL (1)	PL183468B1 (pt)
RU (1)	RU2135514C1 (pt)
SG (1)	SG52834A1 (pt)
TR (1)	TR199600664A2 (pt)
TW (1)	TW464654B (pt)
ZA (1)	ZA966555B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0903146A1 (en) *	1997-09-23	1999-03-24	Applied Research Systems ARS Holdings N.V.	21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
WO1999017779A1 (en)	1997-10-06	1999-04-15	The Board Of Trustees Of Leland Stanford Jr. University	Methods for treating psychosis associated with glucocorticoid related dysfunction
EP1726307A3 (en) *	1997-10-06	2007-04-04	The Board Of Trustees Of The Leland Stanford Junior University	Methods for treating psychosis associated with glucocorticoid related dysfunction
KR20010043630A (ko)	1998-05-15	2001-05-25	더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티	치매의 치료를 위한 글루코코티코이드 수용체 길항제
JP2002541153A (ja) *	1999-04-06	2002-12-03	アクゾ・ノベル・エヌ・ベー	経口活性アンドロゲン
MXPA03007261A (es) *	2001-02-14	2006-03-09	Abbott Lab	Moduladores del receptor de glucocorticoides.
EP1285927A3 (de)	2001-08-16	2005-06-29	Schering Aktiengesellschaft	Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
DE60209248D1 (de) *	2001-10-26	2006-04-20	Akzo Nobel Nv	Verwendung von (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propinyl)-estra-4,9-dien-3-on zur behandlung von schweren depressionen
US8193172B2 (en)	2001-11-23	2012-06-05	Pop Test Cortisol Llc	Methods for the treatment of major depressive disorder using glucocorticoid receptor antagonists
CA2504751C (en) *	2002-11-05	2013-02-05	Corcept Therapeutics, Inc.	Methods for treating gastroesophageal reflux disease
WO2004069202A2 (en) *	2003-02-04	2004-08-19	Corcept Therapeutics, Inc	Antiglucocorticoids for the treatment of postpartum psychosis
TW200820977A (en)	2006-08-08	2008-05-16	Organon Nv	Use of glucocorticoid receptor antagonists for treatment of infectious conditions
EP2671086B1 (en) *	2011-02-03	2018-04-25	Pop Test Oncology LLC	System and method for diagnosis and treatment
US20120245552A1 (en) *	2011-03-23	2012-09-27	Pop Test Cortisol Llc	Combination Therapy
EP3434274A1 (en)	2011-03-31	2019-01-30	Pop Test Oncology LLC	Prevention of infection
WO2012145258A1 (en) *	2011-04-18	2012-10-26	Pop Test Cortisol Llc	Hair loss treatment
US8986677B2 (en)	2012-07-30	2015-03-24	Pop Test Cortisol Llc	Therapeutic compositions and methods
US9878138B2 (en)	2014-06-03	2018-01-30	Pop Test Abuse Deterrent Technology Llc	Drug device configured for wireless communication
CN107530435A (zh) *	2015-03-02	2018-01-02	科赛普特治疗学股份有限公司	使用糖皮质激素受体拮抗剂和生长抑素治疗acth分泌型肿瘤
WO2016154203A1 (en)	2015-03-23	2016-09-29	Evestra, Inc.	Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents
WO2016160969A1 (en)	2015-03-30	2016-10-06	Corcept Therapeutics, Inc.	Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
US9598459B2 (en) *	2015-08-03	2017-03-21	Pop Test Oncology Llc	Pharmaceutical compositions and methods
EP3400233B1 (en) *	2015-08-03	2025-10-22	Pop Test Oncology LLC	Pharmaceutical compositions and methods
KR20180052120A (ko)	2015-08-13	2018-05-17	코어셉트 쎄라퓨틱스, 잉크.	Acth-의존성 쿠싱 증후군을 감별 진단하는 방법
EP3394079A4 (en) *	2015-12-23	2019-08-21	Oric Pharmaceuticals, Inc.	INHIBITORS OF GLUCOCORTICOIDREZEPTORS
EP3394078A4 (en) *	2015-12-23	2019-11-27	Oric Pharmaceuticals, Inc.	INHIBITORS OF THE GLUCOCORTICIDE RECEPTOR
WO2017112904A1 (en)	2015-12-23	2017-06-29	Oric Pharmaceuticals, Inc.	Inhibitors of glucocorticoid receptor
KR102197526B1 (ko)	2016-01-19	2020-12-31	코어셉트 쎄라퓨틱스 인코포레이티드	이소성 쿠싱 증후군의 감별 진단
CN111690031B (zh)	2016-10-07	2021-06-01	欧瑞克制药公司	糖皮质激素受体抑制剂
JP7670462B2 (ja)	2017-06-20	2025-04-30	コーセプトセラピューティクス，インコーポレイテッド	選択的グルココルチコイドレセプターモジュレーターを使用して神経上皮腫瘍を処置する方法
AU2020239920A1 (en)	2019-03-18	2021-11-04	Arnold L. Newman	Method of improving insulin sensitivity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA8231B (en) *	1981-01-09	1982-11-24	Roussel Uclaf	New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2522328B1 (fr) *	1982-03-01	1986-02-14	Roussel Uclaf	Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
US4780461A (en) *	1983-06-15	1988-10-25	Schering Aktiengesellschaft	13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3625315A1 (de) *	1986-07-25	1988-01-28	Schering Ag	11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
IE60780B1 (en) *	1987-01-23	1994-08-10	Akzo Nv	New 11-aryl steroid derivatives
DE3708942A1 (de) *	1987-03-18	1988-09-29	Schering Ag	19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3717169A1 (de) *	1987-05-19	1988-12-01	Schering Ag	19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3723788A1 (de) *	1987-07-16	1989-01-26	Schering Ag	11(beta)-phenyl-4,9,15-estratriene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3822770A1 (de) *	1988-07-01	1990-01-04	Schering Ag	13-alkyl-11ss-phenylgonane
ES2127181T3 (es) *	1989-08-04	1999-04-16	Schering Ag	11-beta-aril-gona-4,9-dien-3-onas.
EP0712311B1 (en) *	1993-08-04	1998-10-07	Akzo Nobel N.V.	Antiglucocorticoid steroids for the treatment of anxiety disorders
ZA953976B (en) *	1994-05-19	1996-01-19	Akzo Nobel Nv	11,21-bisphenyl-19-norpregnane derivatives

1996
- 1996-07-29 IL IL11897496A patent/IL118974A/en not_active IP Right Cessation
- 1996-08-01 ZA ZA9606555A patent/ZA966555B/xx unknown
- 1996-08-06 CA CA002182771A patent/CA2182771C/en not_active Expired - Fee Related
- 1996-08-12 JP JP21282496A patent/JP3977462B2/ja not_active Expired - Fee Related
- 1996-08-13 CZ CZ19962386A patent/CZ287740B6/cs not_active IP Right Cessation
- 1996-08-13 DK DK96202273T patent/DK0763541T3/da active
- 1996-08-13 DE DE69603425T patent/DE69603425T2/de not_active Expired - Lifetime
- 1996-08-13 EP EP96202273A patent/EP0763541B1/en not_active Expired - Lifetime
- 1996-08-13 ES ES96202273T patent/ES2137625T3/es not_active Expired - Lifetime
- 1996-08-13 AT AT96202273T patent/ATE182596T1/de active
- 1996-08-14 BR BR9603429A patent/BR9603429A/pt not_active IP Right Cessation
- 1996-08-14 KR KR1019960033671A patent/KR100445376B1/ko not_active Expired - Fee Related
- 1996-08-14 SG SG1996010458A patent/SG52834A1/en unknown
- 1996-08-15 TR TR96/00664A patent/TR199600664A2/xx unknown
- 1996-08-15 NZ NZ299181A patent/NZ299181A/en not_active IP Right Cessation
- 1996-08-16 NO NO963427A patent/NO306257B1/no not_active IP Right Cessation
- 1996-08-16 AU AU62119/96A patent/AU711369B2/en not_active Ceased
- 1996-08-16 HU HU9602269A patent/HU229023B1/hu not_active IP Right Cessation
- 1996-08-16 PL PL96315733A patent/PL183468B1/pl not_active IP Right Cessation
- 1996-08-16 CN CN96111830A patent/CN1129602C/zh not_active Expired - Fee Related
- 1996-08-16 RU RU96115774/04A patent/RU2135514C1/ru not_active IP Right Cessation
- 1996-08-16 AR ARP960104036A patent/AR003982A1/es unknown
- 1996-08-22 TW TW085110266A patent/TW464654B/zh not_active IP Right Cessation
1997
- 1997-09-22 US US08/935,360 patent/US6011025A/en not_active Expired - Lifetime
1999
- 1999-08-31 GR GR990402198T patent/GR3031116T3/el unknown

Also Published As

Publication number	Publication date
GR3031116T3 (en)	1999-12-31
NZ299181A (en)	1997-09-22
RU2135514C1 (ru)	1999-08-27
CZ238696A3 (en)	1997-05-14
IL118974A (en)	2001-09-13
NO963427L (no)	1997-02-18
JPH09104696A (ja)	1997-04-22
ES2137625T3 (es)	1999-12-16
EP0763541A1 (en)	1997-03-19
EP0763541B1 (en)	1999-07-28
TW464654B (en)	2001-11-21
TR199600664A2 (tr)	1997-03-21
IL118974A0 (en)	1996-10-31
ATE182596T1 (de)	1999-08-15
AU6211996A (en)	1997-02-20
HK1002010A1 (en)	1998-07-24
KR100445376B1 (ko)	2004-11-08
DE69603425D1 (de)	1999-09-02
PL315733A1 (en)	1997-03-03
US6011025A (en)	2000-01-04
HU229023B1 (en)	2013-07-29
NO306257B1 (no)	1999-10-11
HUP9602269A3 (en)	1997-12-29
CN1147520A (zh)	1997-04-16
CA2182771C (en)	2007-04-24
AR003982A1 (es)	1998-09-30
HUP9602269A2 (en)	1997-04-28
KR970010784A (ko)	1997-03-27
HU9602269D0 (en)	1996-10-28
MX9603476A (es)	1997-07-31
PL183468B1 (pl)	2002-06-28
DE69603425T2 (de)	2000-01-20
CN1129602C (zh)	2003-12-03
ZA966555B (en)	1997-02-19
SG52834A1 (en)	1998-09-28
CA2182771A1 (en)	1997-02-18
JP3977462B2 (ja)	2007-09-19
NO963427D0 (no)	1996-08-16
DK0763541T3 (da)	2000-02-28
AU711369B2 (en)	1999-10-14
CZ287740B6 (en)	2001-01-17

Publication	Publication Date	Title
BR9603429A (pt)	1998-05-12	Derivado de 11-(fenila substituída) estra-4,9-dieno processo de preparação do mesmo composição farmacêutica e uso deste derivado
EE9500064A (et)	1996-06-17	Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid
EE200000319A (et)	2001-08-15	hGRF-PEG konjugaatide saitspetsiifiline valmistamismeetod, hGRF-PEG konjugaadid, nende vaheühendid, kasutamine ja farmatseutiline kompositsioon
CY2013003I1 (el)	2014-07-02	Φωσφονοκεφεμικα παραγωγα, διαδικασια για την παρασκευη τους, και χρηση αυτων
FI955235L (fi)	1996-05-03	Oksatsolidiinionijohdannaiset, niiden valmistus ja käyttö
FI951468L (fi)	1995-10-01	Lipopeptidijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö
EE200000225A (et)	2001-06-15	Arüüloksüalküüldialküülamiinid, nende valmistamismeetodid ja farmatseutiline kompositsioon
BR9707501A (pt)	1999-07-27	Composto composição farmacêutica e uso do composto
EE9800302A (et)	1999-02-15	Arüülglütsiinamiidi derivaadid, nende valmistamismeetod ja kasutamine ning farmatseutiline preparaat
KR100547921B1 (ko)	2006-10-19	설폰아미드-치환된크로만,이의제조방법및이를포함하는약제학적조성물
FI971268A7 (fi)	1997-03-26	Menetelmä 1,3-alkaanidiolien ja 3-hydroksialdehydien valmistamiseksi
FI990134L (fi)	1999-03-24	Pyridatsino-(4,5-beta)-kinoliini-5-oksidijohdannaisia, niiden valmistus ja niiden käyttö glysiiniantagonisteina
EE03825B1 (et)	2002-08-15	2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
BR9707808A (pt)	1999-07-27	Composto composição farmacêutica e uso do composto
EE200000226A (et)	2001-06-15	3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
EE200000651A (et)	2002-04-15	Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE9800145A (et)	1998-10-15	Fenüülamidiini derivaadid, meetodid nende valmistamiseks ja nende kasutamine arstimitena
FI960813A7 (fi)	1997-08-23	Menetelmä alkyylieetterien ja niiden seosten valmistamiseksi
FI953384L (fi)	1996-01-13	Uusi bentsolitiaditsiiniyhdiste, menetelmä sen valmistamiseksi ja sitä sisältävät farmaseuttiset koostumukset
FI970997L (fi)	1997-03-10	Bentsosykloalkeeniyhdisteet, niiden valmistus ja käyttö
BR9612413A (pt)	1999-07-13	Composto uso do mesmo e composição farmacêutica
BR9602025A (pt)	1998-10-06	Composto composição farmacêutica uso e processo para a preparação de um composto
FI972988A0 (fi)	1997-07-14	Menetelmiä ja farmaseuttisia koostumuksia, joissa käytetään desmetyyliselegiliiniä
EE03996B1 (et)	2003-04-15	Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
FI960316L (fi)	1996-03-22	Oksatiolaanit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset

Legal Events

Date	Code	Title	Description
2002-04-02	FB34	Technical and formal requirements: requirement - article 34 of industrial property law
2003-09-23	FB36	Technical and formal requirements: requirement - article 36 of industrial property law
2003-12-23	HJEG	Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
2004-05-18	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2004-09-28	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
2007-06-19	B25A	Requested transfer of rights approved	Owner name: N.V. ORGANON (NL) Free format text: TRANSFERIDO DE: AKZO NOBEL N.V.
2012-01-31	B25A	Requested transfer of rights approved	Free format text: TRANSFERIDO DE: N.V. ORGANON
2015-06-23	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 19A ANUIDADE.
2015-11-24	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2320 DE 23-06-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.